Virtual Library

Start Your Search

Fangfang Shen



Author of

  • +

    P1.13 - Targeted Therapy (Not CME Accredited Session) (ID 945)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.13-21 - Clinical Efficacy and Safety of Apatinib Combined with EGFR - TKIs in Advanced Non-Small Cell Lung Cancer with EGFR - TKIs Resistance (ID 13638)

      16:45 - 18:00  |  Author(s): Fangfang Shen

      • Abstract
      • Slides

      Background

      Acquired resistance to EGFR-TKIs frequently occurs in advanced non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations. Previous studies have shown that apatinib (a TKI against VEGFR-2) combined with EGFR-TKIs might improve the survival of EGFR-TKIs resistant NSCLC patients. We conducted this trial to investigate the efficacy and safety of apatinib combined with EGFR-TKIs compared with traditional chemotherapy for EGFR-TKIs resistant NSCLC patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      This prospective study enrolled advanced NSCLC patients who acquired resistance to the EGFR-TKIs therapy. Patients received apatinib combined with EGFR-TKIs (apatinib in start dose of 250 mg+pior EGFR-TKIs dose) or chemotherapy ( pemetrexed or vinorelbine with platinum). Efficacy was evaluated every 6 weeks based on RECIST 1.1. This study was registered on Chinese Clinical Trail Registry, and the registration number was ChiCTR-OIN-17012051.

      4c3880bb027f159e801041b1021e88e8 Result

      From Mar 2017 to May 2018, 24 patients were enrolled, including 18 patients received apatinib combined with EGFR-TKIs, 6 patients received chemotherapy. In the apatinib group, 83.33%(15/18) patients were available evaluated. The objective response rate was 20% (3/15) and the disease control rate was 100% (15/15). All patients have different degrees of lesion shrinkage. Till May 1, 2018, the median duration of apatinib group treatment was 187 days, and the median PFS has not researched. The most common adverse events in the apatinib group were hypertension, proteinuria, weakness. Five (27.78%) grade 3 hypertension, 3 (16.67%) grade 3 proteinuria and 1 (5.56%) grade 3 diarrhea were observed. Two patients who failed treatment with osimertinib received osimertinib combined with apatinib, got lesions decreased after one cycle. One of the two patients was treated as fifth line treatment. Two patients with brain metastases in the apatinib group got metastases lesions decreased. Two progressive patients got lesions decreased after apatinib dose increasing to 500mg. Of the 7 patients receiving chemotherapy, 6 patients were available evaluated. The objective response rate was 16.67%(1/6) and the disease control rate was 100% (6/6). Major adverse reactions were digestive tract reaction and myelosuppression.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Apatinib combined with EGFR-TKIs may provide a new therapy strategy for NSCLC patients with acquired EGFR-TKIs resistance. Both drugs are oral, which is advantageous in improving the patient's quality of life and the compliance of therapy. Further study with lager samples are needed to validate our findings. Moreover, We will further explore the correlation between genetic mutations, biomarkers and therapeutic efficacy.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.